Candriam SCA’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Candriam SCA’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-5,400	Closed	-$294K	–	827
2020 Q3	$294K	Hold	5,400	–	–	﹤0.01%	740
2020 Q2	$277K	Buy	+5,400	New	+$271K	﹤0.01%	738

Other funds holding IHE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Candriam SCA's IHE Position: Q4 2020 in Review

Candriam SCA sold out of iShares US Pharmaceuticals ETF (IHE) in Q4 2020, closing a stake of 5,400 shares — an estimated $294K sold.

Candriam SCA first reported a position in IHE in Q2 2020 and held it in 2 quarters. The position peaked at $294K in Q3 2020. 99 funds tracked by Wall St. Rank hold IHE as of Q4 2020.

Candriam SCA reported no remaining iShares US Pharmaceuticals ETF position as of Q4 2020 after selling out during the quarter.
Candriam SCA sold 5,400 iShares US Pharmaceuticals ETF shares in Q4 2020, an estimated $294K.
Candriam SCA first reported a position in iShares US Pharmaceuticals ETF in Q2 2020 and held it in 2 quarters.
Candriam SCA's iShares US Pharmaceuticals ETF position peaked at $294K in Q3 2020.
99 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q4 2020.

Based on Candriam SCA's 13F filing for Q4 2020, filed 22 Jan 2021.